BRPI1005372A2 - metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas - Google Patents

metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas

Info

Publication number
BRPI1005372A2
BRPI1005372A2 BRPI1005372A BRPI1005372A BRPI1005372A2 BR PI1005372 A2 BRPI1005372 A2 BR PI1005372A2 BR PI1005372 A BRPI1005372 A BR PI1005372A BR PI1005372 A BRPI1005372 A BR PI1005372A BR PI1005372 A2 BRPI1005372 A2 BR PI1005372A2
Authority
BR
Brazil
Prior art keywords
furostene
furostane
spirostene
spirostane
homeostasis
Prior art date
Application number
BRPI1005372A
Other languages
English (en)
Portuguese (pt)
Inventor
Orsi Antonia
Rees Darly
Howson Patrick
Hu Yaer
Xia Zongqin
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of BRPI1005372A2 publication Critical patent/BRPI1005372A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
BRPI1005372A 2009-01-24 2010-01-22 metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas BRPI1005372A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14708409P 2009-01-24 2009-01-24
CN2009070319 2009-01-24
PCT/GB2010/050098 WO2010084356A1 (en) 2009-01-24 2010-01-22 Treatment of neurotrophic factor mediated disorders

Publications (1)

Publication Number Publication Date
BRPI1005372A2 true BRPI1005372A2 (pt) 2018-03-06

Family

ID=41800830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005372A BRPI1005372A2 (pt) 2009-01-24 2010-01-22 metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas

Country Status (12)

Country Link
US (1) US20120034193A1 (enExample)
EP (1) EP2389182A1 (enExample)
JP (1) JP2012515754A (enExample)
KR (1) KR20110115589A (enExample)
AU (1) AU2010207597A1 (enExample)
BR (1) BRPI1005372A2 (enExample)
CA (1) CA2750510A1 (enExample)
EA (1) EA201190115A1 (enExample)
IL (1) IL214242A0 (enExample)
MX (1) MX2011007842A (enExample)
SG (1) SG173094A1 (enExample)
WO (1) WO2010084356A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130043197A (ko) * 2010-07-20 2013-04-29 파이토팜 피엘씨 엘-도파, 도파민 효능제 및/또는 도파민 증강제 유도된 장애의 치료
US8708906B1 (en) * 2011-09-07 2014-04-29 Allen J. Orehek Method for the prevention of dementia and Alzheimer's disease
RU2501562C1 (ru) * 2012-11-01 2013-12-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук ФГБУ "НИИ фармакологии" СО РАМН Средство, обладающее церебропротекторной активностью
WO2014100433A1 (en) * 2012-12-19 2014-06-26 Brown University Methods for treatment of microcephaly associated autism disorders
WO2017218697A1 (en) * 2016-06-17 2017-12-21 The Trustees Columbia University In The City Of New York Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
CA3036688A1 (en) * 2016-09-12 2018-03-15 University Of South Florida Neuroregeneration improved by ketone
EP4245368A3 (en) 2016-12-21 2024-01-03 Universitäts-kinderspital Beider Basel Migraine prevention and treatment
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
BR102017016550A2 (pt) 2017-08-01 2019-03-19 Lisis Rojo Gomes Uso de glicosídeos esteroidais, formulações farmacêuticas, uso de extratos da planta furcraea foetida, processo de obtenção de extratos da planta furcraea foetida e método de tratamento de distúrbios da pele
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
US11617772B2 (en) 2018-09-11 2023-04-04 Direct Digital Llc Nutritional supplements and therapeutic compositions comprising probiotics
WO2021195477A1 (en) 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
KR102779301B1 (ko) 2021-12-13 2025-03-13 한국한의약진흥원 근위축 개선, 예방 또는 치료용 조성물
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0102416A1 (en) 1982-08-23 1984-03-14 Nutrisearch Company Blends of egg albumen and whey protein of improved gel strength
JP4740426B2 (ja) 1997-03-17 2011-08-03 ビーティージー・インターナショナル・リミテッド 治療用組成物
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DK1066042T3 (da) 1998-03-26 2006-12-18 Phytopharm Plc Steroidale saponiner til behandling af Alzheimers sygdom
EP1123094B1 (en) 1998-09-15 2007-04-11 Btg International Limited Therapeutic compositions (ii)
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
DE10162058A1 (de) * 2001-12-17 2003-07-24 Cospharcon Gmbh Gefäßaktive, juckreiz- und entzündungslindernde Zubereitung zur Minimierung der unangenehmen Begleiterscheinungen hämorrhoidaler Affekte und Ekzeme im Analbereich sowie als unterstützende Maßnahme zur Intertrigo- und Dekubitus-Prophylaxe bei entsprechend disponierten Personen.
WO2003082893A2 (en) 2002-03-27 2003-10-09 Phytopharm Plc Theraputic methods and uses of sapogenins and their derivatives
MXPA04009321A (es) * 2002-03-27 2005-01-25 Phytopharm Plc Metodos y usos terapeuticos de sapogeninas y sus derivados.
US7354956B2 (en) * 2002-04-12 2008-04-08 L'oreal Composition containing a sapogenin and use thereof
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
PT1706121E (pt) * 2004-01-12 2008-12-04 Solvay Pharm Bv Inibidores de endopeptidase neutra (nep) e endopeptidase humana solúvel (hsep) para profilaxia e tratamento de distúrbios neurodegenerativos
NZ548926A (en) * 2004-02-09 2009-07-31 Regenion Gmbh Inhibitors of TGF-R signaling for treatment of CNS disorders
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
CN1692914B (zh) 2004-04-29 2010-05-26 中国人民解放军军事医学科学院放射医学研究所 知母皂苷bⅱ在制备用于防治脑卒中药物或产品中的用途
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds

Also Published As

Publication number Publication date
EP2389182A1 (en) 2011-11-30
US20120034193A1 (en) 2012-02-09
CA2750510A1 (en) 2010-07-29
EA201190115A1 (ru) 2012-02-28
MX2011007842A (es) 2012-01-12
IL214242A0 (en) 2011-09-27
SG173094A1 (en) 2011-08-29
JP2012515754A (ja) 2012-07-12
KR20110115589A (ko) 2011-10-21
AU2010207597A1 (en) 2011-08-18
WO2010084356A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
BRPI1005372A2 (pt) metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas
BRPI0907663A8 (pt) composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
BRPI0821636A2 (pt) Uso de um agente de mascaramento de sabor, composição líquida, e, uso da composição líquida
CL2008000022A1 (es) Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
BRPI0905784A2 (pt) Uso de um composto esteramida, processos de preparação de um composto esteramida e composto esteramida
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
HK1220472A1 (zh) 神经活性类固醇、组合物、及其用途
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0820009A2 (pt) Composições nutracêuticas contendo extrato de estévia ou constituintes do extrato de estévia e uso das mesmas
BR112012020628A2 (pt) fotoiniciador de éter polialquílico, uso de um fotoiniciador de éter polialquílico, método para curar uma composição de matriz, e, composição de matriz
BRPI0820899A2 (pt) Formulação cosmética, e, uso da composição
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
BRPI0814811A2 (pt) Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem
CL2014002493A1 (es) Polipeptidos de relaxina modificados; composicion que lo contiene y sus usos (div. sol. 475-2013)
BRPI0906936A2 (pt) Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarina
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
BRPI0821720A2 (pt) Aplicação de líquidos iônicos, magnéticos como agente de extração
BRPI1006996A2 (pt) composição, método e uso
BR112012029606A2 (pt) formulação, método para a fabricação de uma fomulação, método de tratamento de uma planta e uso de uma formulação
EP2340297A4 (en) COMPOSITION, ITS MANUFACTURING METHOD AND USE
BR112012008202A2 (pt) processo de preparação de uma composição, componentes e uso da composição
IL285088A (en) Cannabinoid containing composition, methods of preparation and use thereof
BR112013003039A2 (pt) éter de celulose não-iônico, método para produzir o éter de celulose, composição, método e uso do éter de celulose não iônico
BRPI1013051A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para fazer uma composição imunogênica, e, kit.
EP2285394A4 (en) ESTROGENIC EXTRACTS OF ANEMARRHENA ASPHODELOIDES BGE FROM THE LILIACEAE FAMILY AND ITS USES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]